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Focus on Wilms’ Tumor
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Dear Colleagues,
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Wilms’ tumor, a cancer of the kidney
unique to children, is the topic of this
year’s Annual Report. This type of kidney
cancer is unrelated to the cancer most
often seen in adults. This tumor and the
discussion that follows highlight the
advances that have taken place in
childhood cancer and the origins of that
success. The National Wilms’ Tumor
Study Group (NWTS) was a
collaborative effort of pediatric
specialists in Oncology, Surgery, Radiation
Therapy, and Pathology from institutions
throughout North America. These
institutions sequentially designed clinical
trials based on prior research findings.
This collaboration was the most effective
way to study and improve outcomes of
such a rare tumor. Children’s Mercy
Hospital patients did participate in the
studies designed by this group.
Increased cure rates with minimal or no
long term complications is the focus of
all cancer treatment. The outcomes of
the NWTS research have made it possible to depart from the concept of an
“all out war at all costs” which focused
primarily on eradicating the disease and
give more attention to the prevention of
long term complications. Pediatrics
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specialists in the field of endocrine,
cardiology, and psychology have joined
the battle collectively to treat children
diagnosed with Wilms’ tumor, as well as
other forms of childhood cancer. The
treatment of Wilms’ tumor and all childhood cancers continues to be a
multidisciplinary endeavor.
The diagnosis of Wilms’ tumor continues
to carry risks of mortality and morbidity
which is the rationale for continued
research and clinical trials. The Children’s
Oncology Group (C.O.G.) has taken the
baton from NWTS and continues the
work to improve cure rates while
systematically developing methods to
reduce or alleviate long term side effects
of the treatment. Children’s Mercy
Cancer Center contributes to improved
patient outcomes at a national level as a
participant of C.O.G. The Children’s
Oncology Group is one of the largest
organizations supported by National
Cancer Institute. Our participation
ensures our patients have the most
advanced, up-to-date treatment options
available to them and our physicians and
nurses take part in the design and
oversight of these studies.
The wide array of pediatric specialists at
Children’s Mercy Hospital, partnered with

the advanced diagnostic and treatment
resources, allows multidisciplinary care to
be available to the children of eastern
Kansas and western Missouri. Children’s
Mercy Hospital continues to strive to
improve the care and well-being of
children in Kansas City and the
surrounding region. The Children’s Mercy
Cancer Center Annual Report will detail
how the cancer program contributes to
this initiative.

Alan S. Gamis, MD, MPH
Director of Oncology
Chair, CMH Cancer Care Committee

Dear Colleagues,
The number of children cared for by
Children’s Mercy Hospitals and Clinics
continues to grow at a significant pace.
In 2001 we had 11,297 inpatient
admissions and more than 305,000
outpatient clinic and emergency
department visits; both totals represent
a nearly 10 percent increase over the
previous year.
The Children’s Mercy Cancer Center
has certainly been an integral part of
this growth. Although Wilms’ tumors
represent a relatively small percentage
of the pediatric cancers we see at
Children’s Mercy, they do represent a
cancer in which we have experienced
great success in cure rates. Our
Cancer Center is accredited by the
American College of Surgeons.
This Cancer Care Annual Report is
very important in our efforts to keep
community physicians and others

informed of our progress regarding the
diagnosis and treatment of childhood
cancer. It’s essential that this treatment
involves the support of the entire
family, which we accomplish through a
multidisciplinary approach where each
discipline plays an important role in the
outcome of each patient’s treatment.
Children’s Mercy is nationally
recognized for the unique, familycentered environment which we
provide to meet each child and family’s
individual needs through innovative,
creative venues.
In addition to providing information on
the specific programs available at
Children’s Mercy, this report also
features how our activities relate to
other centers across the country. I
believe our cancer center continues to
be one of the best in the nation, and I
am pleased to share with you this year’s
Cancer Care Annual Report.

Sincerely,

Randall L. O’Donnell, Ph.D.
President and Chief Executive Officer
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MISSION
Patient Care Services:
“Patient Care Services is dedicated to
providing pediatric care that is safe, evidencebased and family centered.”
Hematology/Oncology:
To provide comprehensive care to children
with cancer and blood disorders in a familycentered care environment in an effort to
promote health and well-being. This mission is
accomplished in the following ways:
· Treatment of patients and their families
with compassion in a family-centered
atmosphere that recognizes the physical,
emotional, financial, social, and spiritual
needs of each individual case.
· Delivery of specialized pediatric medical,
nursing, and psychosocial services through
an interdisciplinary team approach.
· Education of patients, families, health care
students, and providers, and the
community about childhood cancer and
blood disorders and the impact these
diseases have on daily living and long term
survival.
· Support of the advancement in the field of
pediatric hematology and oncology
through medical/nursing research.
· Collaboration with the local, regional, and
national organizations to support our
mission and service the community at a
local and regional level.
· Foster an atmosphere of mutual respect
and support in the workplace to enhance
the spirit of teamwork and personal and
professional growth.
· Foster a leadership model that commits
the “person” with the “worker.”

VISION
Patient Care Services:
“Patient Care Services will be recognized as
the leader in pediatric health care services
through a collaborative approach to evidencebased clinical practice, education, and research.”
Hematology/Oncology:
To be the premier hematology/oncology center
in providing extraordinary care for children and
families.

HEMATOLOGY/ONCOLOGY
SECTION STRATEGIC PLAN
GOALS FOR BEST PRACTICE
ENVIRONMENT
· Facilitate seamless care through improved
communication between staff and other
departments.
· Improved quality of care by education,
psychosocial support, community
involvement, and clinical practice.
· To have shared ownership by all members
focusing on improving the effectiveness of
the section.
· Increase community awareness through
outreach, education and research
participation.
· Improve efficiency and productivity of the
entire Hematology/Oncology section.
· To retain experienced and competent staff
by creating a program of rewards/
incentives and staff education.
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2001 Registry Statistics:
(January 1, 1990 Reference
Date)
v 1,001 patients are abstracted in the cancer
registry since 1990.
v 108 patients were added to the registry in
the year 2001.
v Frequency of Diagnosis for 2001: (see
Fig.1)
• Five most frequently occurring
diagnoses for 2001
-Leukemia
-Brain Tumors
-Neuroblastoma
-Lymphoma
- Wilms’ Tumor
v 30 cancer related deaths were recorded in
2001: (see Fig.2)
• 4 deaths had disease diagnosed in
2001, the remaining were diagnosed
prior to 2001.

Class of Case
(ACOS-COC Classification)
Mortality Data - Figure 2

Leukemia
Lymphoid Leukemias
7
Myeloid Leukemias
2
Central Nervous System
Astrocytoma
1
Medulloblastoma
1
PNET
1
Rhabdoid/teratoid tumor, atypical
1
Neuroblastoma
Lymphoma
Hodgkins
1
Non-Hodgkins
2
Osteosarcoma
Hepatocellular Carcinoma
Rhabdomyosarcoma
Germ Cell Tumor
Desmoplastic Small Round Cell Tumor
Malignant Round Cell Tumor

9

Total Number of Mortalities in 2001

30

4

4
3
3
2
2
1
1
1

Children’s Mercy Hospital Cancer Registry 2001 Frequency of Diagnosis - Figure 1

Leukemia
ALL
AML
Central Nervous System
Astrocytoma
Glioma
Primitive Neuroectodermal Tumor
Ependymoma
Medulloblastoma
Pineoblastoma
Atypical Teratoid Rhabdoid Tumor
Choroid Plexus Carcinoma
Benign/Borderline
Lymphoma
Non-Hodgkin’s
Hodgkin’s

28
4
13
3
2
2
1
1
1
1
8

32 (30%)
32 (30%)

8

(7%)

4
4

Objective: To Contribute to
Cancer Surveillance and
Control
v By collecting and maintaining data on all
patients diagnosed and / or treated with
malignancy and selected benign/borderline
tumors at Children’s Mercy Hospitals and
Clinics.
• Abstract data includes information on
cancer type and location, stage or
extent of disease at diagnosis,
treatment received, recurrence, and
follow-up information.
v By providing data to the National Cancer
Data Base, the Missouri Central Cancer
Registry, and physicians to improve the
prognosis for cancer patients.
v By following our cancer patients annually
throughout their lifetime to check on their
health status.
• 95 percent of all CMH cancer registry
patients had their disease status
updated by the end of 2001.
v Participate and organize the approval
process for accreditation from the
American College of Surgeons
Commission on Cancer (ACOS).
Accreditation was granted in July 1999.

Neuroblastoma
Wilms Tumor
Osteosarcoma
Retinoblastoma
Other
Ewing’s Sarcoma
Hepatoblastoma
Rhabdomyosarcoma
Adenocarcinoma
Papillary Carcinoma
Melanoma
Yolk Sac Tumor
Synovial Sarcoma
Neuroendocrine Tumor
Misc. Reportable Conditions
Total Number of Cases for Year

9
6
3
3
15
2
2
2
1
1
1
1
1
1
3

(8%)
(5%)
(3%)
(3%)
(14%)

108

Class of Case (ACOS-COC
Classification) – Fig. 3
v During the abstracting process a classof
case is assigned according to the criteria
set forth by the ACOS. The class of case
determines whether a case must be
included in the registry
• Class 0 includes patients diagnosed at
CMH but received all of their first
course of treatment elsewhere. In
2001- 0 Cases met this criteria.
• Class 1 includes patients diagnosed at
CMH who received all or part of their
first course of treatment at CMH. In
2001- 81 Class 1patients were
recorded.
• Class 2 includes patients diagnosed
elsewhere and received all or part of
their first course of treatment at CMH.
In 2001 – 15 Class 2 cases were
reported.
• Class 3 includes patients diagnosed
elsewhere who receive their first
course of treatment at another facility.
These patients later have recurrence
and come to CMH for subsequent
treatment. In 2001- 1 Class 3 case was
reported.

v Class of Case 0-2 are followed annually to
determine survival and disease status.
Benign and Borderline Tumors
v These tumors are included in the registry
by agreement of the Cancer Care
Committee.
v Determination for inclusion is the location
of the tumor (e.g. central nervous system)
or its propensity to recur and/or progress
to malignancy.
v Eleven Benign and Borderline Tumors were
reported for 2001 (see Fig. 3)

Reference Date
v The Commission on Cancer
(COC) of the American
College of Surgeons requires
a start date for data
collection to begin. This date
is controlled by the facility
through the guidance of the
Cancer Care Committee and
is approved by the COC.
• January 1, 1990 is the
reference date for the
Children’s Mercy Hospital
effective April 17, 2001.

Class of Case (ACOS-COC Classification) - Figure 3

Class 0
0
(0%)
Diagnosed at CMH - received all of first course of treatment elsewhere.
Class 1
81
(75%)
Diagnosed at CMH - received all of first course of treatment at CMH.
Class 2
15
(14%)
Diagnosed elsewhere - received all or part of first course of treatment at CMH.
Class 3
1
(1%)
Diagnosed elsewhere - received all of first course of treatment
elsewhere.
Benign/Borderline
11
(10%)
Included in the Registry due to location (tumor of central nervous
system), or because of its propensity to recur.

A Five-Year Comparison of
Most Frequently Occurring Diagnoses
at Children’s Mercy Hospital

Total Cases
97

Central Nervous System 25
Leukemia 21
Lymphoma 15
Neuroblastoma 1
Wilm’s Tumor 9
Rhabdomyosarcoma 2
Osteosarcoma 1
Others 11

Total Cases
85
Central Nervous System 31
Leukemia 26
Lymphoma 12
Neuroblastoma 5
Wilm’s Tumor 4
Rhabdomyosarcoma 3
Osteosarcoma 1
Others 15

Total Cases
92

Central Nervous System 19
Leukemia 30
Lymphoma 8
Neuroblastoma 7
Wilms’ tumor 4
Rhabdomyosarcoma 5
Osteosarcoma 2
Others 17

Total Cases
97

Central Nervous System 22
Leukemia 24
Lymphoma 16
Neuroblastoma 4
Wilm’s Tumor 7
Rhabdomyosarcoma 4
Osteosarcoma 6
Others 14

Neuroblastoma 9
Wilm’s Tumor 6
Rhabdomyosarcoma 2
Osteosarcoma 3
Others 16

Lymphoma 8

Central Nervous System 32
Leukemia 32

TOTAL DIAGNOSES

Total Cases
108
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Elizabeth
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Elizabeth is an energetic 6year-old who enjoys tap dancing,
ballet, and crafts. She also likes to
sew clothes for her dolls and bears.
Elizabeth came to Children’s Mercy
in February 2002 and has
successfully completed her
treatment for Wilms’ tumor.
Elizabeth’s older
sister noticed a
strange mass
around her
stomach while
giving Elizabeth a
bath one day.
After seeing their
pediatrician, they
arrived at
Children’s Mercy
and Elizabeth had
surgery the following day.

Nancy. “She went back to school
and finished the year.”
Nancy was very impressed with all
the attention and support they
received at Children’s Mercy.
“A lot of people we had met in the
hospital came in and checked on
us,” says Nancy. “Even the nurse
that originally
checked us in at
Emergency came
back to see how
Elizabeth was doing.”
Elizabeth says that
she doesn’t mind
coming back to the
Oncology Clinic at
Children’s Mercy
because she likes to
do all the crafts.

“Elizabeth did great after the
surgery,” says Elizabeth’s mother,

9
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Epidemiology
Wilms’ tumor is the most common
primary tumor of the kidney and the third
most common solid tumor in children.
Approximately 460 new cases are diagnosed
per year in the United States. For unilateral
Wilms’ tumor, the M:F ratio is 0.92:1.00. The
tumor is slightly more common in the AfricanAmerican population, and significantly less
common in Asian populations. The mean age
at diagnosis is 42 months for males and 47
months for females.
Clinical Presentation
Wilms’ tumor often presents as an
abdominal mass observed by a parent while
bathing the child. Other signs and symptoms
include abdominal pain, gross hematuria,
hypertension (found in 25% of cases), fever, and
anemia. Typically on exam, a large flank mass
can be palpated. It is important to document
the occurrence of any congenital anomalies
such as aniridia, hemihypertrophy and
genitourinary abnormalities. Of those patients
that present with metastases at diagnosis, the
majority (approximately 80%) will have disease
in the lungs as the only site.
Work-up
Evaluation of the patient with suspected
Wilms’ tumor includes baseline laboratory
work to assess renal function, liver function,
coagulation and hematologic status.
Ultrasound is often the initial imaging study
and usually helps to identify the origin of the
mass. Once a renal-based mass is identified in
a child, ultrasound is utilized to evaluate the

vascular system for tumor thrombus. If
present, the extent of tumor thrombus should
be documented. If the thrombus extends
above the level of the hepatic veins, surgical
resection of the mass is delayed until after
chemotherapy is given in an attempt to shrink
the thrombus and lessen the risk of morbidity
associated with the surgery. After ultrasound, a
CT of the abdomen is obtained to further
evaluate the origin and extent of tumor, as well
as to assess the opposite kidney for disease.
Chest radiographs are obtained to evaluate for
pulmonary metastases. Chest CT is usually
obtained as well. A small percentage of patients
may have lung nodules present on CT of the
chest but not visualized by plain films. The
management of these patients is controversial,
as many of these nodules that are identified
only by CT are not metastatic disease.
Surgery
In a multidisciplinary approach to Wilms’
tumor, the surgeon is responsible for resection
of all viable tumor, if possible, and for providing
accurate staging so that the appropriate
adjuvant therapy can be utilized. With this in
mind, in North America, most patients with a
single isolated Wilms’ tumor without
complicating factors such as metastatic disease
or renal tumor vein or inferior vena caval
extension, undergo initial radical nephrectomy
with nodal sampling and evaluation of the
contra-lateral kidney both by palpation and
visualization. However, if there is evidence of
the above-mentioned complicating factors or if
it felt by the surgeon that the tumor is of such
a large size that tumor spillage would be likely,

then initial biopsy followed by adjuvant therapy
is appropriate. In the case of known bilateral
disease, the objective is to preserve as much
renal parenchyma as possible. Therefore, the
patient usually undergoes laparotomy with
biopsy of each tumor as well as lymph node
sampling to facilitate accurate staging. Adjuvant
therapy is usually initiated following histologic
evaluation of the biopsy material. Following
appropriate adjuvant therapy, partial
nephrectomy on each side is then performed, if
possible. On occasion, it may be necessary to
perform a unilateral nephrectomy on one side
and a partial nephrectomy on the other side if
one of the lesions is so large that a partial
nephrectomy is not possible.
In those patients who are felt to be
candidates for initial unilateral radical
nephrectomy by the surgeon, a generous
subcostal incision is made which usually
extends into the conralateral subcostal region.
Often, either the liver or spleen and the colon
or small bowel are adherent to the tumor, but
are not being invaded by the tumor, and are
dissected free from the tumor capsule. Due to
the large size of the tumor, it is usually not
possible to ligate the renal artery or vein
initially. Rather, the surgeon attempts to dissect
the tumor away from adherent organs or
structures and ligates and divides the artery and
vein as one of the last steps. The ureter is
usually ligated and divided as close to the pelvic
rim as possible. Once the tumor is removed,
lymph nodes are taken from the ipsilateral renal
hilar area as well as the periaortic region and
the contralateral kidney is assessed. Following
closure of the incision, a portacath is often

placed under the same anesthesia for
postoperative chemotherapy, but this
procedure may be delayed for a later date in
certain circumstances.
In those patients in whom a biopsy is
initially performed, a small incision is made
along the line of the planned larger incision for
the second operation as this small incision and
the dissection through the abdominal wall
should be excised at the second operation to
remove all residual tumor. An appropriate
biopsy is then taken from the tumor in this
fashion. This procedure is not as simple as it
sounds as the tumors are quite vascular and
bleeding can be a problem from the small
tumor biopsy site.
Pathogenesis and Pathology
Wilms’ tumor is a malignant neoplasm
that recapitulates the histologic appearance of
a human developing fetal kidney, albeit
disorganized (Figure 1). Microscopically,
Wilms’ tumors express of an array of cell types
and tissue components, including differentiating
epithelial and stromal derivatives as well as
undifferentiated blastema, which are normally
not seen after 36 weeks of human fetal
development. In a small proportion of people,
these developing cells may persist within the
kidney beyond 36 weeks of gestation and are
called “nephrogenic rests.” Most of these rests
ultimately undergo spontaneous involution
within the first year of life. It is believed that
some of these rests, before they involute, serve
as the seeds from which Wilms’ tumors may
germinate. Most often the rests are tiny in size
and not detected without a microscope.

Rarely rests can be seen with the naked eye
and may be multiple and cover much of the
entire kidney, a condition referred to a
“nephroblastomatosis.” Whether microscopic
in size or visible to the naked eye, nephrogenic
rests are benign growths and are believed to
represent the first “hit” in the two-hit
hypothesis of malignant transformation. The
second “hit” is believed to be some other
genetic or chromosomal change that imparts a
full malignant potential to these rests. Once
malignant transformation has occurred, these
tumors are often very aggressive, grow
extremely rapidly to large palpable abdominal
masses that may weigh in excess of three
pounds and quickly metastasize to liver, lungs
and lymph nodes.
Aggressive as they may be, even in the
face of spread beyond the confines of the
kidney of origin, 95% of all Wilms’ tumors are
very sensitive to chemotherapy with excellent
overall prognosis. The other 5% are resistant
to chemotherapy and have a much worse
prognosis if they have escaped the confines of
the kidney of origin and the potential to be
completely removed surgically. This distinction
in chemosensitivity can be reliably predicted
based on several microscopic features of
Wilms’ tumors that collectively define the two
histologic grades of the tumor, i.e. “nonanaplastic” or “favorable histology” (Figure 1)
and “anaplastic” or “unfavorable histology”
Wilms’ tumor (Figure 2). There are three
features that define the so-called “anaplastic”
unfavorable tumor: 1. abnormally large nuclei; 2.
nuclear hyperchromicity (unusually dense
nuclear chromatin that reflects abnormally

increased amounts of DNA and chromosomal
duplications); 3. Atypical mitoses that also
reflect excessive genetic material within tumor
cells and disorganized cell division.
The principle role of the pathologist is to
evaluate the biopsy and nephrectomy
specimens for the following: 1. establish that
the renal tumor is a Wilms’ tumor and not one
of the other benign and malignant tumors that
occur in children less frequently; 2. determine
whether the primary tumor has been
completely resected or not; and 3. establish
whether the tumor has favorable or
unfavorable histology. In addition, the
pathologist may selects portions of the tumor
for ancillary genetic, research or other clinical
studies.
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Figure 1: Non-anaplastic favorable Wilms’ tumor
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Stage

I

Tumor confined to the kidney and
completely resected. No penetration
of the renal capsule or involvement of
renal sinus vessels.

II

Tumor extends beyond the kidney but
is completely resected (negative
margins and lymph nodes). At least
one of the following has occurred:
(a) penetration of the renal capsule,
(b) invasion of the renal sinus vessels,
(c) biopsy of tumor before removal,
(d) spillage of tumor locally during
removal.

III

Gross or microscopic residual tumor
remains postoperatively, including
inoperable tumor, positive surgical
margins, tumor spillage involving
peritoneal surfaces, regional lymph
node metastases, or transected tumor
thrombus.

IV

Hematogenous metastases or lymph
node metastases outside the
abdomen (e.g., lung, liver, bone, brain).

V

Bilateral renal Wilms’ tumors at onset.

Figure 2: Anaplastic unfavorable Wilms’ tumor

Staging
The well-established National Wilms’
Tumor Study Group (NWTSG) Staging System
is utilized for patients with Wilms’ Tumor
(Table 1). Patients with unresectable tumors
must be assumed to have at least Stage III
disease and treated as such. Wilms’ tumor may
appear to be unresectable on CT because of
possible invasion of the liver. However, direct
visualization at surgery usually reveals a clear
plane between tumor and the liver and
resection will be possible. Because of the need
for extensive sampling of the tumor to
determine histology and prognosis, surgical
resection is preferred over biopsy when at all
possible desired to reduce the risk of late
effects.

Description

Genetics & Molecular Biology
Several genes are known to predispose
to Wilms’ tumor (WT). WT1, located on the
chromosome 11 short arm at band p13, is
deleted in Wilms’ tumors associated with the
WAGR syndrome (Wilms’ tumor, Aniridia,
Genitourinary anomalies, mental Retardation).
Individuals with the WAGR syndrome have a
30% risk of WT. Denys-Drash syndrome (DDS)
is associated with point mutations of the WT1
gene. DDS is characterized by
pseudohermaphroditism, early renal failure with
diffuse mesangial sclerosis, and Wilms’ tumor.
Germline WT1 mutations are found in only
~5% of patients with sporadic WT.
A second WT gene, “WT2”, located at
11p15, is linked to Beckwith-Wiedemann
syndrome (BWS), an overgrowth syndrome
with a 5-10% risk of WT. The WT2 locus has
10 imprinted genes, including insulin-like
growth factor-2 (IGF2), H-19, and p57Kip2
(CDKN1C), which have been implicated in
Wilms’ tumorigenesis.
Approximately 1% of Wilms’ tumors are
familial with one or more family members with
the disease. The mode of inheritance is
thought to be autosomal dominant with
variable penetrance and expressivity. Linkage
analysis has shown two loci in addition to the
WT1 and “WT2” loci to be linked to WT
predisposition in families with WT; FWT1 on
chromosome 17q and FWT2 on 19q. Still
other families show no linkage to WT1, “WT2”,
FWT1, or FWT2 suggesting other WT
susceptibility genes exist.

Treatment
Since the NWTSG was formed in 1969,
five clinical trials have been completed. CMH
participated and evaluated patients on these
clinical trials. The benefits of national
collaboration are clear. Two-year survival rates
have risen from 20% to greater then 90% for
Wilms’ tumor through the work of the
NWTSG. Furthermore, therapy for certain
subgroups has been reduced to minimize
toxicity and cost of therapy, with continued
excellent outcomes. The results of the
NWTSG trials have allowed us to stratify
treatment by stage and histology, so that the
patient receives the least amount of therapy
necessary. Treatment of the patient with

Outcomes
From 1992-2001, 46 patients have been
diagnosed with Wilms’ tumor at Children’s
Mercy Hospital, with a mean of 5.5 new cases/
year for the past six years. Favorable histology
was found in 44 patients at CMH, 56% males
and 44% females. Of those patients with
favorable histology, overall survival is 91% with
a median follow-up of 42.5 months (range 0119 months).
Figure 3 compares the overall survival
rates of CMH patients with Stage I-IV Wilms’
tumor, favorable histology with the NWTS-4
survival rates. One patient was diagnosed with
Stage V, favorable histology at CMH which is
not reported in figure 3.
Future goals include the ability to
prospectively identify those patients at risk for
relapse using biologic markers. Once identified,
treatment for these patients could be
intensified. Further reductions in therapy for
those patients that are at minimal risk of
relapse are desired to reduce the risk of late
effects.

N=6

N=14

N=13

N=10

Percent Survival

Wilms’ tumor requires the expertise and
collaboration of the surgeon, pathologist,
pediatric oncologist and radiation oncologist to
achieve such excellent outcomes. Careful
resection, accurate staging, postoperative
chemotherapy, and radiation therapy are all key
components in the management of these
patients. Pulse-intensive chemotherapy is given
utilizing Vincristine and Dactinomycin for
patients with Stage I & II Favorable Histology.
Adriamycin and radiation is added for those
patients with Stage III & IV FH disease.

Figure 3: Overall survival (%) for Favorable Histology
Wilms’ Tumor patients treated at CMH compared to
patients treated on NWTS-IV study (Green, DM, et al. J Clin
Oncol 16:3744-3751, 1998). The CMH results are skewed
due to the small sample size (44) compared to 863 pts on
NWTS-IV with Stage II-IV. The CMH patients were treated on
or followed the most current NWTS clinical trials.

Survival Graph
Cumulative Percent Survival

The WT1 gene, the most extensively
studied gene, has 10 exons with a molecular
weight of 45-49 kilodaltons. WT1 encodes a
zinc-finger transcription factor and is critical to
normal kidney and gonadal development. WT1
is a tumor suppressor gene. Function of the
normal WT1 gene is regulation of transcription
of other genes that influence cell growth,
differentiation, and apoptosis.
Cytogenetic, comparative genomic
hybridization (CGH), and loss of heterozygosity
(LOH) studies of Wilms tumor tissue have
found recurring genetic abnormalities. Loss of
chromosome 16q loci (~10-20% of tumors)
and deletions on chromosome 1p (~10% of
tumors) are associated with an adverse
prognosis independent of tumor stage and
histopathology. Mutations of the p53 gene,
located on chromosome 17p, are associated
with anaplasia, a poor prognostic indicator.
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Figure 4: The overall survival rate for patients treated at
CMH with favorable histology, Stage I-IV Wilms’ tumor
from 1992-2001.
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Nicholas
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Nicholas is a busy 3-year-old
boy. He loves books and animals,
particularly dinosaurs. He also
enjoys swimming and playing with
cars.
Nicholas has been a patient at
Children’s Mercy since April 2002
and finished up his
treatment in
September.
When Nicholas’
parents noticed a
hard mass on his
side, they took him
to the pediatrician
and were sent
directly to Children’s
Mercy.
After being
diagnosed with
Wilms’ tumor,
Nicholas went right
into surgery to have his left kidney
removed. After a week in the

hospital, Nicholas went back home
to his books and dinosaurs.
Nicholas’ mother Amy said that
support from family and from the
hospital helped them get through
the difficult time.
“There is all kinds of
support at Children’s
Mercy,” says Amy.
“Not just from
doctors and nurses.
The whole thing is
very impressive.”
Amy thinks that
Nicholas’ young age
helped him through
his battle.
“You have no idea
what to expect when
you get into
something like this,”
says Amy. “But he has been a real
trooper.”
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Hematology/Oncology Section
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The Section of Hematology/
Oncology
The Section of Hematology/Oncology at
Children’s Mercy Hospitals and Clinics has four
distinct services that support the care of
children with malignant or hematologic
disorders. The Regional Hemophilia Center
supports seven sites in a five-state region to
provide comprehensive treatment for both
adult and pediatric patients with bleeding
disorders, as well as coagulation/thrombosis
disorders. The Sickle Cell Disease Service
offers specialized care to this unique population
of patients in an effort to effectively treat acute
and chronic pain, as well as long term sequelae
related to sickle cell disease. The Bone Marrow
Transplant Service provides hematopoeitic stell
cell rescue to patients receiving ablative
therapy and requiring marrow rescue. This is
done utilizing umbilical stem cells, matchedrelated donor cells, and matched-unrelated
donor cells. This service participates in a
national marrow search program and has cells
available to them from all across the world.
The Oncology Service is dedicated to the
treatment of malignant disorders. Each service
has a designated director of service and the
section has a section chief and a section
manager who oversee the medical, nursing,
research, and operations. The section is
comprised of approximately 145 faculty/staff.
Hospital/Interdepartmental
Collaboration
• Children’s Mercy Cancer Care Committee
– meets quarterly
• Tumor Boards – meets weekly for a
minimum of 48 meetings annually
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Bone Marrow
Transplant Service

Sickle Cell
Disease Service

Oncology Service
(Cancer Center)

Regional
Hemophilia Center

Patient Care
Committee
Education
Committee

Performance Improvement
Committee
Points of Service

BMT
Unit

Inpatient
Unit

Outpatient
Unit

Infusion
Room

Services Provided
•
•
•
•
•
•
•

•
•
•

Oncology
Hematology

•
•

Hemophilia
Sickle Cell

Bone Marrow Transplantation Meeting –
weekly
Hematology/Oncology Multidisciplinary
Team – meets weekly
Hematology/Oncology Inpatient Rounds –
meets on 4HT daily
Patient Care Conferences – done as
needed and can be requested by any team
member
FACT Committee (Psychosocial team, child
psychologist, social worker, pastoral care,
child life, music therapist, nursing) – meets
weekly
Hematology/Oncology Section Meeting –
monthly
Senior MD Staff Meeting – 2-3 times
monthly
Physician Assistant/Advanced Practice
Nurse Meeting – 3 times per month

•
•
•
•
•
•
•
•
•
•
•
•

Coagulation
Brain Tumors

•

Outreach

MD/Physician Assistant/Advanced Practice
Nurse Meeting – monthly
Patient Care Services Leadership Council
(hospital-wide committee) – meets weekly
Nursing Practice Council (hospital-wide
committee) – meets monthly
MEDS Committee (hospital-wide
committee) – meets twice monthly
Transfusion Committee – meets every
other month
Hematology/Oncology Core Charge Nurse
Meeting – monthly
Hematology/Oncology Updates – meets
quarterly
COO/VP of Patient Care Services Meeting
– monthly
CEO Assembly – meets monthly
Hematology/Oncology Patient Care
Committee – meets monthly

•
•
•
•
•

Hematology/Oncology Education
Committee – meets monthly
Hematology/Oncology Performance
Improvement Committee – meets
quarterly and on an “as needed” basis
Hematology/Oncology Research Meeting –
monthly
Hematology/Oncology Journal Club –
meets monthly
Children’s Mercy Cancer Center (auxiliary)
– Board of Directors meets every other
month.

Hematology/Oncology
Structure Description
Patient Care Committee
• Works in collaboration with all four
services.
• Efficient utilization of resources to include
labor, supplies, and physical space. This
would include the development,
implementation, and ongoing evaluation of
a staffing/patient ratio and skill mix.
• Promotion of the standard delivery of
patient care to include order templates,
preprinted orders, treatment guidelines,
and/or clinical pathways.
• Promotion of a well defined, timely
discharge process.
• Provide a “seamless care” environment to
include 4HT, H/O Clinic, and CMH Home
Care.
• Promotion of interdepartmental
collaboration to eliminate impediments to
patient care. The collaboration includes
pharmacy, surgery, laboratory, radiology,
and home care.
• Foster an environment that provides peer/
staff recognition.

•

Foster professional development through
specialty certification, committee activity,
nation/local association involvement
(APON, C.O.G., National Hemophilia
Association, National Sickle Cell
Foundation, National Bone Marrow
Consortium).

Education Committee
• Works in collaboration with all four
services.
• Foster creative/innovative approaches to
providing staff education which include, but
are not limited to: poster presentations,
“bathroom ed,” self-learning modules,
individualized orientation plans, and formal/
informal inservices.
• Support the reduction/elimination of
medication/treatment related errors in
collaboration with the patient care
committee through the education of staff.
• Provide up-to-date educational material to
patients/families to include: parent
notebooks, Care Cards, Medication Cards,
and other educational tools; i.e. S.C.O.R.E.
cards.
• Provide a hospital-based chemotherapy
competency validation process for staff
that includes knowledge assessment
(written test) and safe handling/
administration (demonstration/application)
which allows for routine revisions/updates,
as appropriate.
• Develop parent classes to provide a
“classroom-like” setting for parents/
caregivers to be educated about the impact
of a child diagnosed with cancer to include
clinical, psychosocial, financial, and

•

orientation to hospital/community
resources.
Develop a “back-to-school”/school reentry education program for patients and
siblings experiencing childhood cancer/
hematological disorders.

Performance Improvement Committee
• Works in collaboration with all four
services, but “enhancements for Oncology
Service” are under the oversight/direction
of the Cancer Care Committee.
• Foster an environment of continuous
evaluation and improvement of patient
care outcomes.
• Incorporate all staff in process
improvement to include medical, nursing,
psychosocial team, nutrition team, etc.
• Provide ongoing education/information to
staff regarding PI activity and outcomes (i.e.
PI bulletin board).
• Foster interdepartmental process
improvement (i.e. Emergency Medicine,
PICU, laboratory, etc).
• Support the TEAM model for process
improvement.
• Provide a system for “quick assessment and
change” to include task forces.
Pediatric Hematology/Oncology
Fellowship Program
The fellowship program at Children’s
Mercy Hospital trains the future pediatric
hematology/oncology specialists to conduct
patient care and research. Pediatric
hematology/oncology fellows at Children’s
Mercy are fully trained pediatricians who
dedicate a minimum of three years of training in
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hematology/oncology medicine and research.
The first year is dedicated primarily to clinical
care and becoming familiar with procedures.
The subsequent two years are dedicated
heavily to clinical and laboratory research.
Children’s Mercy Hospital currently supports
three fellowship positions for the Hematology/
Oncology Section.
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The Children’s Mercy Hospital
Cancer Care Committee
The Children’s Mercy Hospital Cancer
Care Committee is a standing medical staff
committee that is charged with overseeing the
Oncology services within the hospital. It is
chaired by the Director of Oncology and has
both physician and non-physician members (see
member listing). Numerous associated
specialties that also participate in the care of
oncology patients are represented on the
committee. It meets quarterly and reviews the
patient acuity, programmatic efforts and needs,
and quality assurance efforts that are related to
Oncology services. This committee oversees
the study and enhancement activities of the
cancer program as required by the American
College of Surgeons’ accreditation.
The Children’s Mercy Cancer
Center Tumor Board Meetings
The Children’s Mercy Tumor Boards
represent discussions about newly diagnosed,
recurrent, and unusual oncology patients. All
patients diagnosed at Children’s Mercy Hospital
are discussed in this conference. The
conference consists of a review of the patient’s
history, physical findings at diagnosis, laboratory
values, radiological exams, surgical

interventions, and pathology findings. This is
followed by a review of the patient’s
therapeutic options, current therapy, response
to therapy, and anticipated prognosis. This is
attended by physicians including specialists from
oncology, surgery, radiology, pathology,
orthopedic surgery, otolaryngology,
neurosurgery, ophthalmology, neurology, neuropsychology, rehabilitation medicine,
endocrinology, and radiation therapy.
Additionally, advanced practice nurses, staff
nurses, nursing management, dieticians,
pharmacists, social workers, child life therapists,
chaplaincy, and other members of the patient’s
multidisciplinary team are in attendance. This
provides a forum for general review, education,
and invited input and enhances the
multidisciplinary team approach for children
with cancer utilized at Children’s Mercy
Hospital. These tumor boards are conducted in
compliance with the American College of
Surgeons’ accreditation requirements.
Parent-To-Parent Program
A program designed to connect parents
who have been through the cancer experience
with parents of newly diagnosed children. The
support one parent can give another is
immeasurable. The program focuses on the
initial phase of the cancer experience; however,
many of these parents develop strong, longlasting relationships as they journey through the
cancer experience together. These volunteer
parents provide a mission statement “To offer
comfort and compassion to all oncology
families, from the comfort and compassion that
we ourselves received.” This program has a
social worker who dedicates 16 hours per

week to designing psychosocial support
activities, both at CMH and outside to promote
the emotional well-being of the parents. The
parents are the focal point of this program and
they lead the initiatives.
Social Work and Community
Services
There are four full-time and two parttime social workers dedicated to the
Hematology/Oncology Section. The primary
focus of this team is to assist the patient and
family in understanding the impact the diagnosis
of cancer will have on their family dynamics and
life style. Social workers are skilled in
counseling patients, parents, and siblings with
issues of grief, anger, and overall well-being.
They have a fundamental knowledge of pediatric
hematology/oncology which provides them with
the framework to support the family in
comprehending the diagnosis and treatment
plans, and, as important, the non-medical
ramifications associated with the treatment of
childhood cancer. The social workers, as well as
other health care team members, assist the
families in recognizing their role as partners in
the care of their child and in recognizing the
community support available to them. The
utilization of this community support is crucial
to the success of any treatment plan.
Child Life Therapist/Music
Therapist
One of the greatest challenges of working
with children is the ability to reach them at
their developmental and cognitive level. The
impact of play and music has been
demonstrated to have a positive effect in the

treatment of childhood cancer. The Section of
Hematology/Oncology is provided with two
full-time child life therapists and a part-time
music therapist. This talented group works with
patients, parents, and siblings to aid in the
adjustment and ongoing support associated
with the diagnosis and treatment of childhood
cancer and hematological disorders. Each of
these therapists is master’s prepared and assists
family members and health care team members
on effective strategies/interventions that allow
patients to make choices and allow them a
sense of self-expression. Medical play utilizing
art, story telling, and music are important
elements in effectively educating and preparing
the pediatric patient for invasive and traumatic
procedures utilizing age-appropriate measures.
Sibling support is an important part of the dayto-day activities of these therapists, as well. The
sibling can be instrumental in assisting the
pediatric patient through the coping process.
Both Child Life and Music therapists are
available in the outpatient and inpatient areas
and they are capable of continuing an
intervention beyond the hospital admission.
Our music therapist is currently participating in
a NIH-funded research initiative to better
define the impact of music therapy as an
intervention in the bone marrow transplant
patient.
Chaplaincy
One full-time chaplain is assigned to the
Hematology/Oncology section to support the
spiritual needs of the patients and their families
and there is a chaplain available 24 hours a day
to all patients. The diagnosis of Wilms’ tumor
can present significant religious/spiritual

questions for the patient and family which can
lead to a crisis of faith as families try to sort out
the questions and emotions that accompany a
diagnosis of cancer. Personal faith and the faith
of the community can be a tremendous source
of hope and strength during this challenging
time. In addition to supporting the patient and
family, the chaplain is an integral part of the
support system for the staff who, too, can
struggle with spiritual/religious and ethical
issues. Children’s Mercy Hospital strives to
support all religious affiliations.
Psychology
Children’s Mercy Hospitals and Clinics
believes that the physical and emotional aspects
of a child’s care are tightly connected,
particularly when diagnosed with childhood
cancer. A full-time psychologist supports the
Hematology/Oncology section in providing
support to the patient, parents, and siblings.
This support ranges from strategies for coping
with a new diagnosis to interventions to
improve medication palatability/intake, which is
extremely challenging in the pediatric patient
population. This psychologist is a member of
the Hematology/Oncology team and the
section of Developmental and Behavioral
Sciences at CMH. The Children’s Mercy Cancer
Center provides funding to support this
position. The majority of psychological services
are provided on an outpatient basis. The
Developmental and Behavioral Sciences section
supports the mentoring/education of
psychology students, as well. Outpatient
appointments are available by calling (816) 2343674.

Nutrition Services
Nutrition and patient outcomes related
to pediatric oncology have been linked closely
over the years. Nutrition is an important
component to aid in the prevention and
correction of nutritional deficiencies, thus
improving the overall well-being of the child
undergoing the treatment of cancer. There is
one full-time and one part-time registered
dietician and a nutrition technician who support
the section of Hematology/Oncology. This
includes nutritional assessments, interventions,
as well as participation in nutrition focused
research/data collection. The nutrition service
provides support in all service areas to include
inpatient, outpatient, and home care.
Pharmacy
The decentralization of pharmacy to the
patient care area demonstrates a strong
multidisciplinary approach to patient care. The
section of Hematology/Oncology is supported
by two clinical pharmacists, one satellite
pharmacist, and one pharmacy technician. Each
of these staff is trained in the safe and proper
handling of chemotherapy in accordance with
current safety regulations. The pharmacy
conducted a satisfaction survey with nursing
staff which demonstrated improved satisfaction
among nursing staff. In addition, medication
error percentage rates continue to be below
the national benchmark. This integration is
closely linked to improved medication delivery/
administration outcomes. This satellite is
located on 4 Henson Tower and supports both
the inpatient and outpatient service sites.
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Nidia

20

Nidia is a carefree 12-year-old
girl who loves to play basketball and
go rollerblading. She also enjoys
reading books.
Nidia has been a
patient at
Children’s
Mercy for
almost a year
while she
received
treatment for
Wilms’ tumor.
Nidia’s mother
noticed a bump
on her
daughter’s
stomach and
took her right
to a doctor to
have it checked
out. After being
sent to Children’s Mercy, Nidia
went straight into surgery to have

the mass removed. She is now
finished with her treatment.
Nidia is very grateful that she was
able to beat the disease.
“I feel very lucky
that I could get
better,” says
Nidia.
Nidia knows that
she could not
have made it
through the
ordeal without
the help from her
family and staff at
Children’s Mercy.
“I want to thank
everybody,” says
Nidia. “Every
doctor and nurse
because without
them, I would still be very sick.”
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Enhancements to Patient Care
Hand-washing Observations

p
a
t
i
e
n
t
c
a
r
e

22

Rationale
Following the movement to a new unit with
private rooms the observations of staff was
that health care providers were not as diligent
about washing hands before and after direct
patient contact. It appeared the clean/new unit
added to less focus on hand-washing than the
previous old unit. In addition, there were
increased concerns addressed by parents
regarding the inconsistency with hand-washing
by health care workers.
Intervention
• Implemented a staff observation process
to identify if there were certain health
care providers that didn’t wash their
hands. The conclusion was there was a
concern regarding all health care providers
with regards to washing hands.
· Brightly colored signs were displayed
throughout the unit to remind health care
providers to wash their hands.
· “Cal-Stat” was initiated as an option for
washing hands when soap/water method
was not an the best option; i.e. timeliness.
The ultimate goal was to ensure hands
were cleansed in accordance with
Infection Control guidelines.
· Incorporated parents/patients as the
observers of hand-washing. There was
limited involvement; i.e. parents didn’t
follow through. It did generate a sense
that patients/parents were included in the
process.

Outcome
· Monitor continued throughout the year
with a consistent compliance rate of 95%
or greater the last two quarters.
· Staff became more sensitive to washing
their hands and observing others.
· Parent/Patient complaints/concerns
decreased; i.e. none noted in the last six
months.
· Will continue to monitor randomly in
2002 as this is a high risk area for our unit.

·

Fever and Neutropenia
Rationale
Fever and Neutropenia present a high risk to
immunocompromised patients with high
mortality/morbidity rates if delay in treatment.
Clinical Practice Guidelines developed several
years ago and “best practice” delivery of
antibiotics identified the first 60 minutes as the
critical time. “Best Practice” is based on
literature and on-site experts. In addition,
many of our patients receive their care in
outside Emergency Rooms when they live > l
hour away which presents challenges with
inconsistency.
Intervention
· Fever and Neutropenia kit had been
developed several years ago, but the
inconsistency of the patients having this
available and the outlying sites utilizing it
was a concern. Thus, a revised kit was
developed with clearer instructions on the
recommended steps to take for a patient

·

·

·

with F&N and the use of the kit. Some
sites feel uncomfortable using the kits and
some use the “practice guidelines,” but will
not utilize the antibiotics. Most utilize the
kit and antibiotics.
A central line instruction video was created
to assist in the education of patients/
families and health care providers. It details
the proper way to draw blood/cultures
from a central line. A disclaimer was
added to note that this video does not
validate competence, but merely assists the
care provider in the proper technique in
working with a central line.
Physician Liaison contacted to follow up
with all incidents where an Emergency
Room did not provide “best practice” care;
i.e. antibiotics within 60 minutes or any
delay in treatment.. A report was given
back to the H/O Education Committee/
section manager by liaison for each
incident.
Nurse manager or designee on 4HT calls
the local ER, when applicable to prepare
them for the potential needs of this patient
in their area. The parents provided verbal
consent before this was done and this is
documented in the medical record
“Progress Note.”
Periodic chart reviews conducted to see if
practice matched closely the clinical
practice guidelines.

Outcome
· Increased compliance with patients/families
having F&N kits with them at home.

Enhancements to Patient Care
· Proactive approach with outlying
Emergency Rooms with notification prior
to discharge, thus improving the
communication between CMH and these
outlying hospitals.
· Michelle McMillan, Physician Liaison,
followed up on all incidents where care fell
below “best practice” standard as defined
by section of Hematology/Oncology at
CMH and supported in the literature.
· Discharge coordinator and staff
communication increased regarding the
criteria for patients having a F&N Kit. Just
living > l hour away was not sufficient.
Discharge coordinator would identify the
availability of adequate medical services
and the patient’s/family’s comprehension
level, as well as other criteria applicable to
that family to determine whether patient
would come directly to CMH or go to
local ER. This alleviated those patients that
would not meet the criteria and improved
compliance with coming directly to CMH.
There are times where a patient would
receive antibiotics much faster by driving
two hours and avoiding the local ER. This
is determined each time by the APN/MD
on call and providing instructions to the
parents; i.e. determining the clinical stability
of the patient and selecting the optimal
mode of transport and provision of care.
· Central Line video is given to new
patients/families as a part of their “Family
Notebook.”

Patient/Family Education

· Central Line instructional video created.

Rationale
This monitor was a continuation from 2000
with increased concern regarding the newly
diagnosed oncology patient and the ability of
any caregiver to comprehend the extent/
complexity of information required. A “mock
teaching session” was conducted by the APN
group to demonstrate this complexity. There
was also a recognition that the parents learn in
a variety of ways and that we need to address
this diversity. In addition, there continued to be
a delay or lack of adequate documentation
regarding the teaching that had occurred and
that this teaching is a continuum that should
flow from service sites.

Outcome
· Decreased incidents of patients/families
not complying with guidelines; i.e.
suspected knowledge deficit/emphasis
regarding the “emergent” items.
· Increased participation in “Family Education
Hour” over time with variety of topics
from clinical items to Managed Care to
“Coping with Stress.” Evaluations have
demonstrated parent satisfaction with the
program.
· Chart Reviews have begun to show a shift
from the APN/Nurse Clinician being
exclusively the ones to initiate teaching to
the staff nurse being the initiator.
· In addition, increased documentation from
other disciplines noted.
· “Essentials” given to each new oncology
patient/family.
· “Know To Go” knowledge assessment
being given by the staff nurse has improved;
however, we continue to see some patients
who do not have this noted in the
documentation.
· Focus on patient/family education in each
H/O Update.
· Will continue to conduct chart reviews
quarterly throughout 2002 as this is a high
risk area.

Intervention
· Multidisciplinary Teaching Record put “online” to allow accessibility by multiple care
sites; i.e. inpatient, outpatient, Home Care.
Initial record included only MD/Nursing
and other disciplines were added over
time.
· “Know To Go” developed and
implemented.
· “Essentials” developed and implemented.
· “Family Education Hour” developed and
implemented.
· Periodic Chart Reviews to track
compliance with “best practice” standard
of teaching being initiated within 24 hours
of new diagnosis or newly placed central
line.
· Additional Care Cards/Medication Cards
were developed.
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Enhancements to Patient Care
Conscious Sedation
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Rationale
Sedation is a high risk procedure requiring
advanced skills by the medical/nursing staff. In
addition, the individuality of each child for the
sedation needs requires that this aspect of our
care be monitored closely for safe practice.
CMH Policy and Procedure is intact and
compliance with staff regarding that policy is
imperative. Also important is the recognition
that procedure activity has increased
significantly in the H/O Clinic.
Intervention
· Conducted chart reviews on >95 % of all
patients who had received conscious
sedation in 2001.
· Provided education each month to staff
regarding the areas of improvement noted
from chart reviews.
· Collaboration with H/O nursing staff and
Sedation Team nursing staff regarding the
safe preparation/delivery of the sedation
drugs; i.e. dilution versus Y connector with
no dilution.
· Chart reviews reflected wide variation in
MD practice for dosing.
· Quarterly reports from Sedation Service
to H/O Section provided with follow up/
response, when applicable.
Outcome
· H/O Clinic: inconsistent compliance with
documentation of pain assessment and
discharge teaching noted throughout the
year. 4HT inconsistent with documentation

·
·
·

·

·

·

regarding all areas of documentation.
Observations/analysis did demonstrate that
documentation does occur most of the
time, but it does not get documented on
Sedation Assessment Form. This is the
goal! Poster presentation developed/
implemented collaboratively with H/O
inpatient/outpatient nurses and Sedation
Team nurses.
Review of CMH Sedation Policy.
MD “Peer Review” in 2002 regarding MD
practices with conscious sedation.
Endorsement of a revised policy on 4 HT
regarding the preparation/administration of
sedation drugs; i.e. Y connector with no
dilution of medications. The observations/
analysis of this group was that the dilution
was an added step which can lead to
errors, thus the elimination of this step
would allow for a more accurate delivery.
“One dose per syringe” medication
preparation implemented. This is defined
as no more than a single dose can be
drawn up in any syringe; i.e. multiple doses
will NOT be drawn up in single syringe for
titration.
Pain Assessment chart reviews initiated in
December which indicate 100% of chart
reviews (n=30) had assessment completed
upon admission to clinic.
Continue to monitor closely in 2002.

Medication Safety
Rationale
The need to deliver/administer medications
safely is a primary focus of all health care
settings. In an environment where
chemotherapy and narcotics are given routinely
this becomes a stronger focus as these
medications are high risk, high volume for a
pediatric hematology/oncology inpatient/
outpatient setting.
Intervention
· Nurse manager/core charge nurses/section
manager review medication events/trending
each month at leadership meeting.
· Nurse manager/section manager participate
in hospital-wide MEDS Committee to
identify strategies for safe delivery/
administration.
· Implemented the “front sheet” MAR for
new medications written within the
previous 24 hours.
· Chemotherapy Task Force continues to
review chemotherapy related medication
events and develop guidelines to improve
medication safety.
· Implemented “chemotherapy writing
guidelines” for physicians, advanced practice
nurses, and physician’s assistants.
Outcome
· 0.088% medication error rate
· Decrease in chemotherapy related errors

Cancer Outreach/Education School Re-entry Program
Participants: Nurse, Social Worker,
Child Life Therapist/Music Therapist
Goals/Objectives:
· Build connections between hospital,
parents/child, and school.
· Identifies hospital personnel as a liaison to
the school.
· Give school staff important information/
allow them to ask questions to give them a
better level of comfort in supporting/
interfacing with the child.
· Peers “school mates” are given accurate
information and are able to ask questions;

goal is to alleviate anxieties regarding
cancer.
· Build a support system for the patient
through peers which will decrease/alleviate
teasing or other comments; diagnosis is out
in the open.
· Provide an opportunity, if appropriate to
that age group, for preventive education on
smoking and sun exposure; i.e. adolescents.
Program Outline:
Common Fears
· Afraid to let go of child

· Child in the care of the school and trusting
the school staff
· Afraid child may get teased, asked a lot of
questions, and/or is unable to answer
questions.
Child’s Work
· School is your child’s job
· Learn social skills
· Peer interactions, as well as, interaction
with teachers/staff
· Learn success and failure, develop problem
solving skills
· Academic environment
· Child can be a child and not a patient;
school can be “normal” and a safe place
Evaluation
· Improved school attendance
· Effective communication between the
school and the health care team.
Other Outreach/Educational
Programs
· Children’s Mercy Cancer Center Website,
www.childrens-mercy.org
· “Family Education Hour”
· Caregiver Handbook
· New Diagnosis Information Packet
· The “Bear Program” for re-integration
back into the school system
· The Parent-to-Parent Referral Program for
new parents
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SPONSOR/
STUDY NO.
1991

STUDY NAME/
PROTOCOL
ALL Treatment for Standard Risk

2961

Phase III Untreated AML or MDS

A2971

Study for patients with Downs syndrome and AML, MDS or TMD

AAML0122

Phase II using FTI, Cis-RA, Ara-C and Fludarabine plus HSCT for JMML

A3961

Neuroblastoma Intermediate Risk patients

A3973

Purged vs Unpurged PBSC for patients with HR NBL

P9641

Treatment for Low-Risk NBL patients

ANBL0032

Phase III study using ch14.18 antibody in high risk NBL following myeloablative tx & autologous SCR

ANBL00P2

Perinatal study: Observation study of NBL

4941L

NWTS Late Effects Study open for all patients 5 years or more s/p treatment

A5971

Treatment for Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma

AHOD00P1

Relapsed HD protocol

P9645

Hepatoblastoma Tx Protocol

AOST0121

Metastatic Osteo w Herceptin Tx

AEWS0031

Tx for Ewing’s/PNET/Askin’s of bone/soft tissue using chemo intensification thru interval compression

99701

High-risk CNS embryonal tumors

99703

Brain tumor protocol with PBSC rescue

A9952

Tx for progressive LGG in less than 10 y.o.

P9934

Brain tumor protocol for non-mets medulloblastoma

O923

Phase I Carboxypeptidase for Tx of MTX overdose

ADVL0011

Temazolamide & CCNU for non-brainstem HGG

ADVL0017

Phase 1 using Flavopiridol

ADVL0018

Ch 14.18 and IL-2 for NBL

ADVL0022

Gemcitabine for ALL

P9761

Phase 2 Irinotecan for Solid Tumors

P9962

IT Topotecan for Meningeal Malignancies

ADVL0022

Phase 2 using Gleevec for Relapsed Solid Tumors — open/active

AORST0121

Phase 2 using Irinotecan w/ VCR & Tirapazime for Relapsed or Progressive Rhabdo — open/active

PCT Lab

Cryopreservation of Autologous or Allogeneic PBSC

COBLT

Cord Blood Transplantation Study: Unrelated Donor Umbilical Cord Blood as an Alternative Source of Stem Cells for Transplantation

COBLT - EXPACC

Cord Blood Transplantation Study: Expanded Access Protocol

Minnesota MT 9501

Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Unrelated Umbilical Cord Blood Transplantation
Schering-Plough

P02095

Open-Label, Limited Access Protocol of Posaconazole for Invasive Fungal Infections (only open for one patient)

NMDP

Data Collection for Matched Unrelated Donor Peripheral Blood Stem cell Transplants for Children where donors were treated with
Growth Factors and Harvested by NMDP Transplant Centers

MSK 01-055

A Pilot Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically
Identical Donor Using TBI, Cyclophosphamide and Fludarabine

CMH Protocol

Stem Cell Transplant Data Registries & Specimen Submissions (IBMTR, PBMTC, NMDP,CRIR)

PBMTC GVH0112

Cytokine Gene Polymorphisms in Pediatric Patients Receiving Tacrolimus or Cyclosporin for GVHD Prophylaxis

COG ASCT0031

COG Phase III Hydroxychloroquine for tx of GVHD

CMH Protocol

Use of Umbilical Cord Blood as a Source of Progenitor Cells for Myeloablative Therapy Rescue

PBMTC #014

Cytokine Mobilized Allogeneic Peripheral Stem Cell Transplantation in Children – A Pediatric Blood and Marrow Transplant
Consortium Study

Clinimac

Ex Vivo T-Cell Depletion (IDE 8598) for Graft vs Host Disease Prophylaxis in Related Haplo-Identical Allogeneic Stem Cell Transplant
Recipients

Clinimac

Single Patient Exemption for Ex Vivo T-Cell Depletion for Graft vs Host Disease Prophylaxis in Related Haplo-Identical Allogeneic
Stem Cell Transplant Recipients

•

Immune Tolerance Induction Study

•

Fibrogammin P for patients with Factor VIII deficiency

•

Hemophilia Growth and Development Study – 3
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•

Safety & Efficacy of Recombinant Factor VIII during Long-Term Prophylaxis/on demand treatment in Previously Untreated Patients
(PUP’s) with Hemophilia A

•

Factor VIII testing Program in PUP’s with Hemophilia A

•

Severe Chronic Neutropenia Registry

•

Universal Data and Serum Specimen Collection System for Hemophilia

•

Franco American Registry

•

STOP II

•

Chlamydia infection as a Risk Factor for Cerebrovascular Disease in Sickle Cell Anemia

•

Morbidity & Risk Factor for Subsequent Strokes in Children with SS Anemia

•

Retro Chart Review of ACS in Patients with SCA

•

Genetic Risk Factors for CVA in Children with HbSS

•

Effects of Codeine Meta Enzyme Activity CYP2D6 in Sickle Cell Patients and Implications for Pain Management

•

MOGIS

•

SS transition of Adolescents to Young Adults

•

Cathlflo Activase(CAPS)

Genentech

•

PROCRIT

Ortho Biotech

•

Voriconazole

Pfizer

•

Urate Oxidase

Sanofi Pharmacueticals

•

Fentanyl

Janssen Pharmacuetica

•

Quality of Life among Childhood Leukemia Patients

KBR

•

Quality of Life with Sickle Disease Patients on Chronic Transfusion

KBR

•

Surviving Childhood Cancer: Implications for Career Development

KBR

PENDING IRB APPROVALS
P9407
Infant ALL Treatment Study
ALTE02CI

28

Late QOL & Effects of NBL Survivors (CCG-3881 & 3891)

Dome JS and Coppes MJ: Recent advances in Wilms’ tumor genetics.
Current Opinion in Pediatrics 14:5-11, 2002.
Grundy RG, et al: Loss of heterozygosity on chromosome 16 in sporadic
Wilms’ tumor. Br J Cancer 78:1181-1187,1998.
Green DM, et al: Effect of duration of treatment on treatment outcome
and cost of treatment for Wilms’ tumor: A report from the national
Wilms’ tumor study group. J Clin Onc 16: 3744-3751, 1998.
Green DM, et al, Wilms’ tumor. In Principles and Practice of Pediatric
Oncology 3rd ed, pg 733-759. Editors: PA Pizzo and DG Poplack, LippincottRaven Pub, Philadelphia,1997.
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Andrews, Walter, MD, Chief

Transplant Surgery

Barker, Gerry, RDH

Dentistry

Bartholomew, Joy, RN, CPON

Hematology/Oncology

Cain, Jill, LAASW, MSW

Hematology/Oncology

Cooley, Linda, MD, Director

Cytogenetics Laboratory

Corse, Cindy, CTR

Medical Records

Covitz Hardy, Lynne, PhD, Clinical Psychologist

Developmental & Behavioral Sciences

Cox, Karen, RN, PhD, Senior Vice President, Patient Care Services

Nursing Administration

Devorin, Barb, RN, MSN, PNP

Neurosurgery

Emami, Abbas, MD

Hematology/Oncology

Fournier, Julie, RN, Charge Nurse II

Hematology/Oncology-Clinic

Gamis, Alan, MD –Chairman, Director, Oncology Services

Hematology/Oncology

Modrcin, Ann C., MD Chief

Rehabilitation Medicine

Gilman, Andrew, MD, Director, Bone Marrow Transplant Service

Hematology/Oncology

Guevel, Wendy, RN, MSN, FNP-C, Surgical Nurse Practitioner

Surgery

Gyves-Ray, Katherine, MD

Radiology

Hetherington, Maxine, MD-Assistant Chairman

Hematology/Oncology

Holcomb, George W. III, MD Surgeon-In-Chief

Surgery

Hornig, Gregory, MD, Chief,

Neurosurgery

Huseman, Carolyn, MD

Endocrinology/Diabetes

Hutto, CJ, RN, CPON, Section Manager

Hematology/Oncology

CANCER CARE BOARD MEMBERS
Klockau, Chris, RPh

Pharmacy/Oncology

Laurence, Kris, Clinical Research Coordinator

Hematology/Oncology

Lewing, Karen, MD

Hematology/Oncology

Marcus, Bette, RN, CPON

Hematology/Oncology

Massey, Vickie, MD

Radiation Oncology

Mick, Kathy, RN, CPON, Education Coordinator

Hematology/Oncology

Morello, Frank, MD

Radiology

Nicklaus, Pam, MD

Otorhinolaryngology

Pribyl, Catherine, RN, MSN, Nurse Manager

Hematology/Oncology

Ryan, Robin, CCRP, Clinical Research Coordinator

Hematology/Oncology

Sale, Doug, RN, Clinical Research Coordinator

Hematology/Oncology

Seal, Annie, CCLS

Child Life

Sharp, Ronald, MD, Director-Burn Unit & Trauma

Surgery-ACOS Liaison

Stegenga, Kristin, RN, MSN, CPON, PCNS

Hematology/Oncology

Walter, Christy, LPN, Assistant Clinical Research Coordinator

Hematology/Oncology

Watanabe, Masayo, MD

Hematology/Oncology

Woods, Gerald, MD, Section Chief

Hematology/Oncology

Zwick, David, MD, Dept. Chairman

Pathology & Laboratory Medicine
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